Zhu Zhu

The paper develops DeepDelivery, an AI platform that identifies human proteins for mRNA delivery, validating 80% of top candidates for efficient, non-inflammatory delivery.

This study shows that terminal modifications of integrin ligands can reprogram their supramolecular organization and function, affecting cell migration without altering the sequence.

This paper introduces OPENER, an engineered eRF1 variant that suppresses nonsense mutations and enables nonstandard amino acid incorporation, showing therapeutic benefits in a Duchenne muscular dystrophy model.